Profil

Mascaux Céline

Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service du Doyen de la Faculté de Médecine et Pharmacie

Main Referenced Co-authors
Sculier, J.P. (53)
Meert, A.P. (44)
Berghmans, T. (43)
Paesmans, M. (36)
Lafitte, J.J. (35)
Main Referenced Keywords
Atomic and Molecular Physics, and Optics (1);
Main Referenced Unit & Research Centers
CREMH - Mind & Health (1)
Main Referenced Disciplines
Oncology (79)
Cardiovascular & respiratory systems (4)
Biotechnology (1)

Publications (total 79)

The most downloaded
6 downloads
Dhont, L., Pintilie, M., Kaufman, E., Navab, R., Tam, S., Shepherd, F., Burny, A., Belayew, A., Tsao, M.-S., & Mascaux, C. (11 February 2015). Helicase-like Transcription Factor expression in Non Small Cell Lung Cancer (NSCLC) is associate with a poor prognosis [Poster presentation]. Télévie's Research Seminar, ULB-Erasme, Belgium. https://hdl.handle.net/20.500.12907/21022

The most cited

533 citations (Scopus®)

Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A. P., Noël, S., Lafitte, J. J., & Sculier, J. P. (17 January 2005). The role of Ras oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British Journal of Cancer, I.F.:4.1150 (92), 131-139. https://hdl.handle.net/20.500.12907/10282

Dhont, L., Mascaux, C., & Belayew, A. (15 October 2015). The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor? Cellular and Molecular Life Sciences, 73, 129-145.
Peer Reviewed verified by ORBi

Dhont, L., Pintilie, M., Kaufman, E., Navab, R., Tam, S., Shepherd, F., Burny, A., Belayew, A., Tsao, M.-S., & Mascaux, C. (11 February 2015). Helicase-like Transcription Factor expression in Non Small Cell Lung Cancer (NSCLC) is associate with a poor prognosis [Poster presentation]. Télévie's Research Seminar, ULB-Erasme, Belgium.

Berghmans, T., Ameye, L., Lafitte, J. J., Colinet, B., Cortot, A., CsToth, I., Holbrechts, S., Lecomte, J., Mascaux, C., Meert, A. P., Paesmans, M., Richez, M., Scherpereel, A., Toussaint, L., Tulippe, C., Willems, L., Dernies, T., Leclercq, N., & Sculier, J. P. (01 January 2015). Prospective validation obtained in a similar group of patients and with similar high throughput biological test failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European Lung Cancer Working Party. Frontiers in Oncology, 4, 1-16.
Peer Reviewed verified by ORBi

Mascaux, C. (15 September 2014). Aspects biologiques du cancer bronchique. Revue des Maladies Respiratoires, 6.

Van Dyck, E., Nazarov, P., Muller, A., Nicot, N., Bosseler, M., Pierson, S., Van Moer, K., Palissot, V., Mascaux, C., Knolle, U., Ninane, V., Nati, R., Bremnes, R., Vallar, L., Berchem, G., & Schlesser, M. (04 February 2014). Bronchial Airway Gene Expression in Smokers with Lung or Head and Neck Cancer. Cancer Medicine, 3 (2), 322-336.
Peer reviewed

Mascaux, C., & Shepherd, F. A. (2014). Treatment strategies in KRAS mutated NSCLC. In S. Peters & B. Besse (Eds.), New therapeutic strategies in lung cancer (pp. 157-185). Springer International Switzerland.

Mascaux, C., & Shepherd, F. (2014). New therapeutic strategies in lung cancer. Treatment strategies in KRAS mutated NSCLC. In New therapeutic strategies in lung cancer. Treatment strategies in KRAS mutated NSCLC (pp. 157-185). Springer International Switzerland.

Mascaux, C., Tsao, M.-S., & Hirsch, F. R. (2014). Molecular testing and lung cancer. In H. I. Pass, D. Ball, ... G. V. Scagliotti (Eds.), The IASLC Multidisciplinary Approach to Thoracic Oncology (pp. 241-259). IASLC press.

Berghmans, T., Ameye, L., Willems, L., Paesmans, M., Mascaux, C., Lafitte, J. J., Meert, A. P., Scherpereel, A., Cortot, A., CsToth, I., Dernies, T., Toussaint, L., Leclercq, N., & Sculier, J. P. (01 November 2013). Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine: a ELCWP prospective study. Lung Cancer, I.F.:3.392 (82 (2)), 340-5.
Peer Reviewed verified by ORBi

Mascaux, C. (01 August 2013). Adjuvant chemotherapy after pulmonary resection for lung cancer. Thoracic Surgery Clinics, 23 (3), 401-10.
Peer Reviewed verified by ORBi

Brothers, J. F., Hijazi, K., Mascaux, C., El-Zein, R. A., Spitz, M. R., & Spira, A. (19 July 2013). Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-NLST era. BMC Medicine, I.F.:6.6800 (11), 168.
Peer reviewed

Peled, N., Wynes, M. W., Ikeda, N., Ohira, T., Yoshida, K., Qian, J., Ilouze, M., Brenner, R., Kato, Y., Mascaux, C., & Hirsch, F. R. (01 July 2013). Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cellular Oncology, I.F.:3.105 (36 (4)), 277-288.
Peer Reviewed verified by ORBi

Zielinski, C., Knapp, S., Mascaux, C., & Hirsch, F. R. (01 May 2013). Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Annals of Oncology, I.F.:7.3800 (24 (5)), 1170-9.
Peer Reviewed verified by ORBi

Mascaux, C., Feser, W. J., Lewis, M., Baron, A. E., Coldren, C. D., Merrick, D. T., Kennedy, T. C., Eckelberger, J. I., Rozeboom, L. M., Franklin, W. A., Minna, J. D., Bunn, P. A. J., Miller, Y. E., Keith, R., & Hirsch, F. R. (01 February 2013). Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prevention Research, I.F.:4.9080 (6 (2)), 1-9.
Peer Reviewed verified by ORBi

Mascaux, C., Ekman, S., Dooms, C., & Shepherd, F. (01 January 2013). Individualized therapy in the adjuvant setting for NSCLC. Current Respiratory Medicine Reviews, 2013 (2), 1-9.
Peer Reviewed verified by ORBi

Christoph, D. C., Asuncion, B. R., Mascaux, C., Tran, C., Lu, X., Wynes, M. W., Gauler, T. C., Wohlschlaeger, J., Theegarten, D., Neumann, V., Hepp, R., Welter, S., Stamatis, G., Tannapfel, A., Schuler, M., Eberhardt, W. E., & Hirsch, F. R. (01 September 2012). Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, I.F.:3.6610 (7 (9)), 1440-1448.
Peer Reviewed verified by ORBi

Mascaux, C., & Wislez, M. (01 January 2012). Les récepteurs à EGF et MET régulent la tumorogenèse et la résistance au gefitinib dans les cancers du poumon par la modulation de l'expression de miARNs. Bulletin du Cancer, I.F.:0.6100 (99 (3)), 235-6.
Peer Reviewed verified by ORBi

Vansteenkiste, J., Dooms, C., Mascaux, C., & Nackaerts, K. (01 January 2012). Screening and early detection of lung cancer. Annals of Oncology, I.F.:6.4250 (23 (suppl.10)), 320-x327.
Peer Reviewed verified by ORBi

Mascaux, C., Wynes, M. W., Yasufumi, K., Tran, C., Asuncion, B. R., Zhao, J., Gustavson, M., Ranger-Moore, J., Gaire, F., Matsubayashi, J., Nagao, T., Yoshida, K., Ohira, T., Ikeda, N., & Hirsch, F. R. (15 December 2011). EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor - A novel antibody for immunohistochemistry or AQUA technology. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, I.F.:7.7420 (17 (24)), 7796-7807.
Peer reviewed

CsToth, I., Anthoine, G., Berghmans, T., Mascaux, C., Paesmans, M., Sculier, J. P., & Meert, A. P. (01 January 2011). C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib. Anticancer Research, I.F.:1.7250 (31), 281-285.
Peer Reviewed verified by ORBi

Kato, Y., Peled, N., Wynes, M. W., Yoshida, K., Pardo, M., Mascaux, C., Ohira, T., Tsubo, M., Matsubayashi, J., Nagao, T., Ikeda, N., & Hirsch, F. R. (01 October 2010). Novel EGFR mutation specific antibodies for NSCLC: Immunohistochemistry as a possible screening method for EGFR mutations. Journal of Thoracic Oncology, I.F.:4.0400 (5 (10)), 1551-1558.
Peer Reviewed verified by ORBi

Hubaux, F., Vandermeers, F., Crisanti, C., Kapoor, V., Burny, A., Mascaux, C., Albelda, S. M., & Willems, L. (01 June 2010). Preclinical evidences for a beneficial impact of valproate in response of small cell lung cancer to first-line chemotherapy. European Journal of Cancer, I.F.:4.9440 (49 (9)), 1724-1734.
Peer Reviewed verified by ORBi

Paesmans, M., Berghmans, T., Dusart, M., Garcia, C., Hossein-Foucher, C., Lafitte, J. J., Mascaux, C., Meert, A. P., Roelandts, M., Scherpereel, A., Terrones Munoz, V., & Sculier, J. P. (01 May 2010). Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. European Lung Cancer Working Party, and on behalf of the IASLC Lung Cancer Staging Project. Journal of Thoracic Oncology, I.F.:4.040 (5 (5)), 612-619.
Peer Reviewed verified by ORBi

Peled, N., Mascaux, C., Wynes, M. W., & Hirsch, F. R. (2010). Lung Cancer: A multidisciplinary Approach to Diagnosis and Management. Chapter 21: Role of Personalized Medicine: Now and the Future. In Demos Medical Publishing (pp. 69-102). Kernstine K.H. and Reckamp K.L.

Mascaux, C., Peled, N., Garg, K., Kato, Y., Wynes, M. W., & Hirsch, F. R. (01 January 2010). Early detection and screening of lung cancer. Expert Review of Molecular Diagnostics, I.F.:4.6520 (10 (6)), 799-815.
Peer Reviewed verified by ORBi

Vandermeers, F., Hubert, P., Delvenne, P., Mascaux, C., Grigoriu, B., Knuutila, S., Burny, A., Scherpereel, A., & Willems, L. (15 April 2009). Valproate, in combination with pemetrexed and cisplatin, provideds additional efficacy to the treatment of malignant mesothelioma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, I.F.:6.7470 (15 (8)), 2818-2828.
Peer reviewed

Mascaux, C., Laes, J. F., Anthoine, G., Haller, A., Ninane, V., Burny, A., & Sculier, J. P. (01 February 2009). Evolution of microRNAs expression during human bronchial squamous carcinogenesis. European Respiratory Journal, I.F.:5.5270 (33), 352-359.
Peer Reviewed verified by ORBi

Mascaux, C. (01 January 2009). Study of the genesis of bronchial epidermoid carcinoma: evolution of the expression of proteins, messenger RNAs and microRNAs at all stages of the process of carcinogenesis. Bulletin et Mémoires de l'Académie Royale de Médecine de Belgique, 164 ((5-6)), 247-254.
Peer Reviewed verified by ORBi

Berghmans, T., Mascaux, C., Haller, A., Meert, A. P., Van Houtte, P., & Sculier, J. P. (01 October 2008). EGFR, TTF1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer, I.F.:2.9700 (62), 35-44.
Peer Reviewed verified by ORBi

Mascaux, C., Bex, F., Martin, B., Haller, A., Paesmans, M., Willard-Gallo, K., Ninane, V., & Sculier, J. P. (01 January 2008). Nucleophosmin and p14arf nucleolar relocalization: a new mechanism of lung squamous carcinogenesis? European Respiratory Journal, I.F.:5.5450 (32), 678-686.
Peer Reviewed verified by ORBi

Alexopoulos, C. G., Berchier, M. C., Berghmans, T., Bonduelle, Y., Colinet, B., Colon, T., Dusart, M., Ficheroulle, X., Giner, V., Kotsori, K., Lafitte, J. J., Leclercq, N., Lecomte, J., Louviaux, I., Markiewicz, E., Mascaux, C., Meert, A. P., Paesmans, M., Richez, M., ... Wackenier, P. (2008). Traitement des cancers bronchiques à petites cellules: maladies étendues. Les recommandations de pratique clinique de l'European Lung Cancer Working Party. Revue Médicale de Bruxelles, (29), 455-472.
Peer Reviewed verified by ORBi

Mascaux, C. (01 January 2008). Cancérogenèse bronchique. Revue des Maladies Respiratoires, I.F.:0.3710 (25), 3S32-3S39.
Peer Reviewed verified by ORBi

Berghmans, T., Dusart, M., Paesmans, M., Hossein-Foucher, C., Buvat, I., Castaigne, C., Scherpereel, A., Mascaux, C., Moreau, M., Roelandts, M., Alard, S., Meert, A. P., Patz, E. F., Lafitte, J. J., & Sculier, J. P. (01 January 2008). Primary tumour standardized uptake value (SUV max) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Journal of Thoracic Oncology, I.F.:3.5080 (3), 6-12.
Peer Reviewed verified by ORBi

Alexopoulos, C. G., Berchier, M. C., Berghmans, T., Bonduelle, Y., Colinet, B., Ficheroulle, X., Giner, V., Kotsori, K., Lafitte, J. J., Louviaux, I., Mascaux, C., Meert, A. P., Paesmans, M., Richez, M., Roelandts, M., Scherpereel, A., Sculier, J. P., Van Houtte, P., & Wackenier, P. (2008). Traitement des cancers bronchiques à petites cellules: maladies limitées. Les recommandations de pratique clinique de l'European Lung Cancer Working Party. Revue Médicale de Bruxelles, (29), 159-167.
Peer Reviewed verified by ORBi

Alexopoulos, C. G., Berchier, M. C., Berghmans, T., Bonduelle, Y., Colinet, B., Collon, T., Dusart, M., Ficheroulle, X., Giner, V., Kotsori, K., Lafitte, J. J., Leclercq, N., Lecomte, J., Louviaux, I., Markiewicz, E., Mascaux, C., Meert, A. P., Paesmans, M., Richez, M., ... Wackenier, P. (2007). European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung Cancer: IV. Extensive diseases. Hospital Chronicles, (2), 118-134.
Peer reviewed

Alard, S., Alexopoulos, C. G., Berghmans, T., Bonduelle, Y., Colinet, B., Colon, T., Desurmont, S., Efremidis, A., Ficheroulle, X., Florin, M. C., Giner, V., Holbrechts, S., Koumakis, G., Lafitte, J. J., Leclercq, N., Louviaux, I., Markiewicz, E., Mascaux, C., Meert, A. P., ... Wackenier, P. (2007). Traitement des cancers bronchiques non à petites cellules: maladies avancées (métastatique). Les recommandations de pratique clinique de l'European Lung Cancer Working Party. Revue Médicale de Bruxelles, (28), 495-511.
Peer Reviewed verified by ORBi

Alexopoulos, C. G., Berchier, M. C., Berghmans, T., Bonduelle, Y., Colinet, B., Ficheroulle, X., Giner, V., Kotsori, K., Lafitte, J. J., Louviaux, I., Mascaux, C., Meert, A. P., Paesmans, M., Richez, M., Roelandts, M., Scherpereel, A., Sculier, J. P., Van Houtte, P., & Wackenier, P. (2007). European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung Cancer: IV. Limited disease. Hospital Chronicles, (2), 74-82.
Peer reviewed

Berghmans, T., Paesmans, M., Mascaux, C., Martin, B., Meert, A. P., Haller, A., Lafitte, J. J., & Sculier, J. P. (01 November 2006). Thyroid transcription factor 1: a new prognostic factor in lung cancer: a meta-analysis. Annals of Oncology, I.F.:5.1790 (17), 1673-1676.
Peer Reviewed verified by ORBi

Mascaux, C., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A. P., Lafitte, J. J., & Sculier, J. P. (17 July 2006). Has Cox-2 a prognostic role in lung cancer? A systematic review of the literature with meta-analysis of the survival results. British Journal of Cancer, I.F.:4.459 (95), 139-145.
Peer Reviewed verified by ORBi

Berghmans, T., Mascaux, C., Martin, B., Ninane, V., & Sculier, J. P. (01 May 2006). Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Lung Cancer, I.F.:3.5540 (52), 219-224.
Peer Reviewed verified by ORBi

Alexopoulos, C. G., Berghmans, T., Berchier, M. C., Bonduelle, Y., Colinet, B., Collon, T., Dequanter, D., Efremidis, A., El Khawad, C., Florin, M. C., Giner, V., Holbrechts, S., Jouveshomme, S., Koumakis, G., Lafitte, J. J., Lecomte, J., Lemaître, J., Lothaire, P., Louviaux, I., ... Wackenier, P. (2006). Traitement des cancers bronchiques non à petites cellules, non métastatiques et non résécable. Recommandations de pratique clinique de l'ELCWP. Revue Médicale de Bruxelles, (27), 152-161.
Peer Reviewed verified by ORBi

Meert, A. P., Martin, B., Verdebout, J. M., Feoli, F., Mascaux, C., Ninane, V., & Sculier, J. P. (01 January 2006). EGFR, c-erbB-2 and Ki-67 in NSCLC and preneoplastic bronchial lesions. Anticancer Research, I.F.:1.4790 (26), 135-138.
Peer Reviewed verified by ORBi

Alexopoulos, C. G., Berghmans, T., Berchier, M. C., Colinet, B., Dequanter, D., Efremidis, A., Florin, M. C., Giner, V., Jouveshomme, S., Koumakis, G., Lafitte, J. J., Lecomte, J., Lemaître, J., Louviaux, I., Mascaux, C., Meert, A. P., Ninane, V., Richez, M., Sculier, J. P., ... Wackenier, P. (2006). European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small cell lung Cancer: III. Metastatic disease. Hospital Chronicles, (1), 169-185.
Peer reviewed

Alexopoulos, C. G., Berghmans, T., Berchier, M. C., Colinet, B., Dequanter, D., Efremidis, A., Florin, M. C., Giner, V., Jouveshomme, S., Koumakis, G., Lafitte, J. J., Lecomte, J., Lemaître, J., Louviaux, I., Mascaux, C., Meert, A. P., Ninane, V., Richez, M., Sculier, J. P., ... Wackenier, P. (2006). European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small cell lung Cancer: II. Unresectable non-metastatic stages. Hospital Chronicles, (1), 108-117.
Peer reviewed

Mascaux, C. (01 January 2006). Reply: K-Ras: a prognostic factor for survival in non-small cell lung cancer. British Journal of Cancer, I.F.:4.4590 (94), 1549.
Peer Reviewed verified by ORBi

Alexopoulos, C. G., Berghmans, T., Berchier, M. C., Colinet, B., Dequanter, D., Efremidis, A., Florin, M. C., Giner, V., Jouveshomme, S., Koumakis, G., Lafitte, J. J., Lecomte, J., Lemaître, J., Louviaux, I., Mascaux, C., Meert, A. P., Ninane, V., Richez, M., Sculier, J. P., ... Wackenier, P. (2006). European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small cell lung Cancer: I. Early stages. Hospital Chronicles, (1), 52-61.
Peer reviewed

Alexopoulos, C. G., Berghmans, T., Berchier, M. C., Colinet, B., Dequanter, D., Efremidis, A., Florin, M. C., Giner, V., Jouveshomme, S., Koumakis, G., Lafitte, J. J., Lecomte, J., Lemaître, J., Louviaux, I., Mascaux, C., Meert, A. P., Ninane, V., Richez, M., Sculier, J. P., ... Wackenier, P. (2006). Traitement des cancers bronchiques non à petites cellules et résécables. Recommandations de pratique clinique de L'European Lung Cancer Working Party. Revue Médicale de Bruxelles, (27), 29-38.
Peer Reviewed verified by ORBi

Mascaux, C., Martin, B., Verdebout, J. M., Ninane, V., & Sculier, J. P. (01 August 2005). COX-2 expression during early lung squamous cell carcinomas oncogenesis. European Respiratory Journal, I.F.:3.9470 (26), 198-203.
Peer Reviewed verified by ORBi

Berghmans, T., Paesmans, M., Meert, A. P., Mascaux, C., Lothaire, P., Lafitte, J. J., & Sculier, J. P. (01 July 2005). Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer, I.F.:3.1720 (49), 13-23.
Peer Reviewed verified by ORBi

Mascaux, C., Iannino, N., Berghmans, T., Meert, A. P., & Sculier, J. P. (2005). Docetaxel as salvage treatment for non-small cell lung cancer: implementation study. Revue Médicale de Bruxelles, (26), 153-158.
Peer Reviewed verified by ORBi

Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A. P., Noël, S., Lafitte, J. J., & Sculier, J. P. (17 January 2005). The role of Ras oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British Journal of Cancer, I.F.:4.1150 (92), 131-139.
Peer Reviewed verified by ORBi

Berghmans, T., Mascaux, C., Martin, B., Ninane, V., & Sculier, J. P. (01 January 2005). Prognostic role of p53 in stage III non-small cell lung cancer. Anticancer Research, I.F.:1.6040 (25), 2385-2390.
Peer Reviewed verified by ORBi

Martin, B., Paesmans, M., Berghmans, T., Lothaire, P., Mascaux, C., Meert, A. P., Lafitte, J. J., & Sculier, J. P. (01 January 2004). The role of Ki-67 expression on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British Journal of Cancer, I.F.:3.7420 (91), 2018-2025.
Peer Reviewed verified by ORBi

Liptay, M. J., Mascaux, C., & Sculier, J. P. (2004). Malignant Tumors of the Lung. Chapter16: TNM Staging. In Malignant Tumors of the Lung. Chapter16: TNM Staging (pp. 183-188). Editions Springer.

Meert, A. P., Feoli, F., Martin, B., Verdebout, J. M., Mascaux, C., Verhest, A., Ninane, V., & Sculier, J. P. (01 January 2004). Ki-67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: a preliminary study. Histopathology, I.F.:2.9550 (44), 47-53.
Peer Reviewed verified by ORBi

Meert, A. P., Martin, B., Paesmans, M., Berghmans, T., Mascaux, C., Verdebout, J. M., Delmotte, P., Lafitte, J. J., & Sculier, J. P. (15 September 2003). The role of HER-2/neu expression the survival of patients with lung cancer: a systematic review of literature. British Journal of Cancer, I.F.:3.8940 (89), 959-965.
Peer Reviewed verified by ORBi

Martin, B., Paesmans, M., Berghmans, T., Branle, F., Ghisdal, L., Mascaux, C., Meert, A. P., Steels, E., Vallot, F., Verdebout, J. M., Lafitte, J. J., & Sculier, J. P. (07 July 2003). Role of Bcl-2 as prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. British Journal of Cancer, I.F.:3.8940 (1), 55-64.
Peer Reviewed verified by ORBi

Mascaux, C., Martin, B., Verdebout, J. M., Meert, A. P., Ninane, V., & Sculier, J. P. (01 May 2003). Fragile histidine triad protein expression in non-small cell lung cancer and correlation with tumour proliferation as estimated by Ki-67 and with p53, a tumour suppressor gene. European Respiratory Journal, I.F.:2.9990 (21), 753-758.
Peer Reviewed verified by ORBi

Berghmans, T., Lafitte, J. J., Mascaux, C., Meert, A. P., Paesmans, M., & Sculier, J. P. (01 January 2003). Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of literature with meta-analysis. Cancer Therapy, I.F.:3.6880 (1), 245-256.
Peer Reviewed verified by ORBi

Meert, A. P., Berghmans, T., Mascaux, C., & Sculier, J. P. (01 January 2003). Réponse immunitaire dans les cancers bronchopulmonaires. Revue des Maladies Respiratoires, I.F.:0.6640 (20), 566-578.
Peer Reviewed verified by ORBi

Berghmans, T., Meert, A. P., Mascaux, C., Paesmans, M., Lafitte, J. J., & Sculier, J. P. (01 January 2003). Citation indexes are not reflecting methodological quality in lung cancer randomised trials. Annals of Oncology, I.F.:3.6050 (14), 715-720.
Peer Reviewed verified by ORBi

Berghmans, T., Paesmans, M., Lalami, Y., Louviaux, I., Luce, S., Mascaux, C., Meert, A. P., & Sculier, J. P. (01 November 2002). Activity of chemotherapy and immunotherapy on malignant mesothelioma : a systematic review of the literature with meta-analysis. Lung Cancer, I.F.:2.4510 (38), 111-121.
Peer Reviewed verified by ORBi

Berghmans, T., Lafitte, J. J., Mascaux, C., Meert, A. P., Paesmans, M., & Sculier, J. P. (01 November 2002). Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of literature with meta-analysis. Lung Cancer, I.F.:1.798 (38), 111-121.
Peer Reviewed verified by ORBi

Delmotte, P., Martin, B., Paesmans, M., Berghmans, T., Mascaux, C., Meert, A. P., Steels, E., Verdebout, J. M., Lafitte, J. J., & Sculier, J. P. (01 October 2002). VEGF et survie des patients atteint d'un cancer pulmonaire. Revue systématique avec méta-analyse. Revue des Maladies Respiratoires, I.F.:0.3000 (19), 577-584.
Peer Reviewed verified by ORBi

Meert, A. P., Paesmans, M., Martin, B., Delmotte, P., Berghmans, T., Verdebout, J. M., Lafitte, J. J., Mascaux, C., & Sculier, J. P. (23 September 2002). The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British Journal of Cancer, I.F.:3.6390 (87), 694-701.
Peer Reviewed verified by ORBi

Meert, A. P., Martin, B., Delmotte, P., Berghmans, T., Lafitte, J. J., Mascaux, C., Paesmans, M., Steels, E., Verdebout, J. M., & Sculier, J. P. (01 September 2002). The role of EGF-R expression on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. European Respiratory Journal, I.F.:2.9310 (20), 975-981.
Peer Reviewed verified by ORBi

Berghmans, T., Paesmans, M., Lafitte, J. J., Mascaux, C., Meert, A. P., & Sculier, J. P. (01 August 2002). Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodology assessment and meta-analysis. Lung Cancer, I.F.:2.4510 (37), 115-123.
Peer Reviewed verified by ORBi

Berghmans, T., Paesmans, M., Lafitte, J. J., Mascaux, C., Meert, A. P., Jacquy, C., Burniat, A., Steels, E., Vallot, F., & Sculier, J. P. (01 April 2002). Therapeutic use of granulocyte and granulocyte-macrophage colony stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Supportive Care in Cancer, I.F.:1.2990 (10), 181-188.
Peer Reviewed verified by ORBi

Meert, A. P., Berghmans, T., Lafitte, J. J., Lemaître, F., Mascaux, C., Paesmans, M., & Sculier, J. P. (01 January 2002). Which progress have the new agents brought for chemotherapy of advanced non-small cell lung cancer? European Respiratory Journal, I.F.:2.9310 (12:84), 208-216.
Peer Reviewed verified by ORBi

Martin, B., Verdebout, J. M., Mascaux, C., Paesmans, M., Rouas, G., Verhest, A., Ninane, V., & Sculier, J. P. (01 January 2002). Expression of p53 in preneoplastic and early neoplastic bronchial lesions. Oncology Reports, I.F.:1.1710 (9), 223-229.
Peer Reviewed verified by ORBi

Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaître, F., Mascaux, C., Meert, A. P., Vallot, F., Lafitte, J. J., & Sculier, J. P. (01 October 2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. European Respiratory Journal, I.F.:2.9890 (18), 705-719.
Peer Reviewed verified by ORBi

Sculier, J. P., Ghisdal, L., Berghmans, T., Branle, F., Lafitte, J. J., Vallot, F., Meert, A. P., Lemaître, F., Steels, E., Burniat, A., Mascaux, C., & Paesmans, M. (04 May 2001). The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. British Journal of Cancer, I.F.:3.9420 (84 (9)), 1150-1155.
Peer Reviewed verified by ORBi

Sculier, J. P., Berghmans, T., Paesmans, M., Branle, F., Lemaître, F., Mascaux, C., Meert, A. P., Steels, E., Vallot, F., & Lafitte, J. J. (01 January 2001). La place de la chimiothérapie dans le traitement des cancers bronchiques non à petites cellules non métastatiques. Revue Médicale de Bruxelles, 22 (6), 477-487.
Peer Reviewed verified by ORBi

Mascaux, C., Martin, B., Paesmans, M., Verdebout, J. M., Verhest, A., Vermylen, P., Bosschaerts, T., Ninane, V., & Sculier, J. P. (01 January 2001). Expression of thrombospondin in non-small cell lung cancer. Anticancer Research, I.F.:1.4160 (22), 1273-1278.
Peer Reviewed verified by ORBi

Meert, A. P., Paesmans, M., Berghmans, T., Martin, B., Mascaux, C., Vallot, F., Verdebout, J. M., Lafitte, J. J., & Sculier, J. P. (01 January 2001). Prophylactic cranial irradiation in small cell lung cancer : a systematic review of the literature with meta-analysis. BMC Cancer, I.F.:1.7020.
Peer reviewed

Bron, D., Meuleman, N., & Mascaux, C. (01 January 2001). Biological basis of anemia. Seminars in Oncology, I.F.:3.6000 (28 (2 suppl 8)), 1-6.
Peer Reviewed verified by ORBi

Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaître, F., Meert, A. P., Vermylen, P., & Sculier, J. P. (01 October 2000). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer, I.F.:1.4010 (30), 23-36.
Peer Reviewed verified by ORBi

Mascaux, C., Leurquin, M., Ninane, V., Delaunois, L., Dargent, J. L., & Sculier, J. P. (01 January 2000). Séance anatomo-clinique: néoplasie prostatique et hémoptysies. Revue Médicale de Bruxelles, 1, 29-33.
Peer Reviewed verified by ORBi

Meert, A. P., Berghmans, T., Branle, F., Lemaître, F., Mascaux, C., Rubesova, E., Vermylen, P., Paesmans, M., & Sculier, J. P. (01 September 1999). Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Research, I.F.:1.3470 (19), 4376-4390.
Peer Reviewed verified by ORBi

Contact ORBi UMONS